Southampton leads world-first COVID-19 vaccine booster study

Covid vaccine trial injection_457x220

Volunteers from Southampton, Portsmouth and Bournemouth will soon be able to receive a third ‘booster’ COVID-19 vaccine through a new clinical trial launching this week, led by Professor Saul Faust at University Hospital Southampton.

The Cov-Boost study, backed by £19.3 million of government funding through the Vaccines Taskforce, will be run at University Hospital Southampton, University Hospitals Dorset and the Portsmouth Research Hub, and is being led by University Hospital Southampton.

First COVID-19 booster trial in the world

It will be the first in the world to provide vital data on the impact of a third dose on patients’ immune responses. The study will give scientists from around the world and the experts behind the UK’s COVID-19 vaccination programme a better idea of how effective a booster of each vaccine is in protecting the individual from the virus.

The initial findings, expected in September, will help inform decisions by the Joint Committee on Vaccination and Immunisation (JCVI) on any potential booster programme from autumn this year, ensuring the country’s most vulnerable are given the strongest possible protection over the winter period.

Trialling seven vaccines as potential boosters

The trial will look at seven different COVID-19 vaccines as potential boosters, given at least 10 to 12 weeks after a second dose as part of the ongoing vaccination programme. One booster will be provided to each volunteer and could be a different brand to the one they were originally vaccinated with.

Vaccines being trialled include Oxford/AstraZeneca, Pfizer/BioNTech, Moderna, Novavax, Valneva, Janssen and Curevac, as well as a control group. The trial has received ethics approval by the NHS Research Ethics Committee, as well as approval from the Medicines and Healthcare products Regulatory Agency.

Taking part

The study will be recruiting participants through the NHS COVID-19 Vaccine Research Registry, with vaccinations set to start from the beginning of June.

Participants will be adults aged 30 years or older and will include those immunised early on in the vaccination programme - for example, adults aged 75 and over or health and care workers.

The study will take place at 16 NIHR-supported sites across the UK, and will include a total of 2,886 patients. All participants will be monitored throughout the study for any potential side effects and will have bloods taken to measure their immune responses at days 28, 84, 308 and 365, with a small number having additional blood tests at other times. All sites will have an electronic diary for all participants that will send alerts to the team in real time if needed and a 24-hour emergency phone to a doctor on the study, who can provide further clinical advice.

All the trial sites are working on ways of including people in research from a wide variety of backgrounds and individuals from ethnic minorities are encouraged to apply.

Those interested can find out more on Twitter @CovBoost and the website covboost.org.

Preparing the UK booster programme

The government is preparing for a potential booster programme based on clinical need and will publish further details in due course. The final policy will be informed by advice from the JCVI and take into account the results of clinical trials.

Professor Saul Faust, Chief Investigator and Director of NIHR Southampton Clinical Research Facility, said:

“This trial will give the Joint Committee on Vaccination and Immunisation the important data to inform their recommendations of how to protect the population against any future wave.

“It is fantastic that so many people across the country have taken part in vaccine trials up to now so that we can be in a position to study the effects of boosters, and we hope that as many people as possible over the age of 30 who received their first dose early in the NHS programme will be able to take part.”

Posted on Thursday 20 May 2021